Enterprise Pharmacy Forward

Sign in Subscribe

Enterprise Pharmacy

Expanding Care Beyond Walls: Launching Geisinger’s Hospital at Home Program

Expanding Care Beyond Walls: Launching Geisinger’s Hospital at Home Program

Michelle Budzyn and Kelly Bolesta Geisinger’s Hospital at Home program is an innovative initiative that offers patients hospital-level care from the comfort of their own homes. The program allows patients to remain close to family, friends and pets; avoid unnecessary exposure to infection; and continue healing in safety

Geisinger Pharmacy value creation in a pluralistic healthcare environment

Geisinger Pharmacy value creation in a pluralistic healthcare environment

Jonathan Brady, Allison Cebulko and Seth Gazes Each year, Enterprise Pharmacy develops a strategic project portfolio aimed at improving organizational financial performance as part of the Geisinger Transformation (GT) program. The pharmacy team operates under a dual mandate: 1. To mitigate overall drug trend while maintaining the quality of care

Transforming cancer care: Expanding home infusion access for blinatumomab therapy

Transforming cancer care: Expanding home infusion access for blinatumomab therapy

Benjamin Andrick, Ron Zsido and Nichole Varela-Gonzalez Over the past year, the health system continued to advance cancer care delivery by expanding access to high-acuity therapies in the home setting. Among the most impactful initiatives was the development and implementation of a coordinated home infusion program for blinatumomab,

Geisinger Cancer Center Dickson City opens, expanding access to advanced oncology care

Geisinger Cancer Center Dickson City opens, expanding access to advanced oncology care

Justine Zuk and Ralph Ferraro On June 23, the new Geisinger Cancer Center Dickson City welcomed its first patient, marking a major milestone in the expansion of advanced cancer care across northeastern Pennsylvania. This momentous occasion reflects the culmination of months of tireless dedication and teamwork. Every member of the

From purchase to patient: Geisinger’s AI-powered approach to drug diversion prevention

From purchase to patient: Geisinger’s AI-powered approach to drug diversion prevention

Barbara Zirnhelt Drug diversion continues to pose a significant and persistent challenge for healthcare systems across the country. Even with strict adherence to professional standards and regulatory requirements, many organizations still lack a fully integrated, systemwide approach to effectively reduce the risks associated with controlled substances. At Geisinger, we have

Tenecteplase is here: Navigating the shift of a stroke thrombolytic in the United States prior to FDA approval: a mini-review on rationale, barriers and pathways

Tenecteplase is here: Navigating the shift of a stroke thrombolytic in the United States prior to FDA approval: a mini-review on rationale, barriers and pathways

Julian M. Burwell, Jason R. Howay, Lisa Wasko, Samantha Doucoure, Jamie L. Kerestes, Clemens M. Schirmer, David Ermak, Anthony Noto, Philipp Hendrix Until March 2025, alteplase (TPA) was the sole thrombolytic agent approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute ischemic stroke (AIS)

Pharmacy Stars platform drives systemwide standardization in compounding competencies

Pharmacy Stars platform drives systemwide standardization in compounding competencies

Heidi Yanoski and Adam Castro Over the past year, the transition of Geisinger’s aseptic technique competencies to the Pharmacy Stars® online platform was successfully completed, with the official launch occurring on March 1, 2025. This initiative involved extensive cross-departmental planning and customization to meet systemwide requirements. Instructional resources